Combination therapy of inhibitors for IGF1 R and PI3K

• Main Authors: HUANG, XIZHONG, CAO, ZHU ALEXANDER, PETERS, MALTE, CHANG, DAVID DONG EUN, GANSERT, JENNIFER LORRAINE, SCHUMACHER, KARL MARIA
• Format: Patent
• Language: English
• Published: 05.02.2015
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to a pharmaceutical combination comprising an alpha- isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine- 1,2-dicarboxylic acid 2-amide l-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin- 4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.